Reach Grant supports researchers conducting late-translational childhood cancer studies to overcome preclinical barriers and advance promising work toward phase I and/or II clinical trials.
Funder: Alex's Lemonade Stand Foundation
Due Dates (Anticipated): April 2027 (Full application)
Funding Amounts: Up to $250,000 USD over two years; maximum $125,000 per year in direct costs
Summary: Supports hypothesis-driven, late-translational childhood cancer research needed to advance toward phase I and/or II clinical trials.
Key Information: A clinical development plan is required; clinical trial expenses are not funded.
Alex’s Lemonade Stand Foundation’s Reach Grant supports preclinical research that removes barriers to translating promising childhood cancer studies into clinical trials. The goal is to advance projects toward a phase I and/or II trial within two to three years after the funded project ends. Appropriate work includes completing IND-enabling studies, generating preclinical data needed for trial development, and validating biomarkers for patient selection.
The program focuses on feasible, hypothesis-driven, late-translational studies grounded in preliminary data. Proposals must include milestones, time-based deliverables, and a plan for clinical development. Projects with a clear clinical trial plan receive priority. Screening, discovery, and early-translational projects are outside the program’s scope.